A new metabolite fromCunninghamella blakesleeana-mediated biotransformation of an oral contraceptive drug, levonorgestrel

Bates Malikovna Kudaibergenova, Atia‐tul Wahab, Mahwish Siddiqui, Zharylkasyn A. Abilov, Muhammad Iqbal Choudhary

2019

Closed access Metadata (CSL-JSON)
DOI 10.1080/14786419.2019.1655018
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Cunninghamella blakesleeana-mediated biotransformation of an oral contraceptive drug, levonorgestrel (1), yielded a new metabolite, 13β-ethyl-17α-ethynyl-10,17β-dihydroxy-4,6-dien-3-one (2), and two known metabolites 3 (13β-ethyl-17α-ethynyl-10β,17β-dihydroxy-4-en-3-one), and 4 (13β-ethyl-17α-ethynyl-6β,17β-dihydroxy-4-en-3-one) at an ambient temperature using aqueous media. Hydroxylation and dehydrogenation of compound 1 was observed during the bio-catalytic transformation. The structure of a new metabolite 2 was determined by 1H, 13C, and 2DNMR and HR-EIMS spectroscopic techniques.